MedTrace Logo

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

NCT04758949 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-01-11

No results posted yet for this study

Summary

Phase 2 trial to study FL-101 alone or in combination with nivolumab in patients who have surgically resectable Non-Small Cell Lung Cancer.

Conditions

Interventions

DRUG

FL-101

200 mg administered intravenously every 2 weeks prior to surgery.

DRUG

Nivolumab

240 mg administered intravenously every 2 weeks prior to surgery.

DRUG

Placebo

200 mg administered intravenously every 2 weeks prior to surgery.

Sponsors & Collaborators

  • Flame Biosciences

    lead INDUSTRY

Principal Investigators

  • Cassandra Choe-Juliak, MD · Flame Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2021-12-22
Completion
2021-12-22
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04758949 on ClinicalTrials.gov